BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/12/2014 8:41:00 PM | Browse: 1066 | Download: 908
Publication Name World Journal of Gastroenterology
Manuscript ID 4354
Country Japan
Received
2013-06-28 09:46
Peer-Review Started
2013-06-28 15:45
To Make the First Decision
2013-07-19 08:38
Return for Revision
2013-07-20 13:23
Revised
2013-07-31 18:34
Second Decision
2013-08-16 19:43
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-08-16 23:29
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-10-21 12:08
Publish the Manuscript Online
2013-11-13 08:37
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Surgery
Manuscript Type Case Report
Article Title Adjuvant surgery for advanced extrahepatic cholangiocarcinoma
Manuscript Source Invited Manuscript
All Author List Yukio Oshiro, Kazuhiro Takahashi, Ryoko Sasaki, Tadashi Kondo, Shingo Sakashita and Nobuhiro Ohkohchi
Funding Agency and Grant Number
Corresponding Author Yukio Oshiro, MD, PhD, Department of Surgery, Division of Gastroenterological and Hepatobiliary Surgery, and Organ Transplantation, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan. oshiro@md.tsukuba.ac.jp
Key Words Extrahepatic cholangiocarcinoma; Adjuvant surgery; Conversion surgery; Chemotherapy; Gemcitabine
Core Tip Patients with Stage Ⅳ cholangiocarcinoma are currently not considered to be surgical candidates and are typically offered systemic chemotherapy. Recently, several novel systemic chemotherapy regimens have allowed an initially unresectable cholangiocarcinoma to be resectable. In a patient with advanced extrahepatic cholangiocarcinoma, gemcitabine (GEM) induced a dramatic reduction of the tumor, which led to curative resection and a long-term survival of 6 years and 9 mo. This result suggests the possibility of advantages of using GEM for the treatment of advanced cholangiocarcinoma, and GEM-based chemotherapy could be performed more often for unresectable cholangiocarcinomas.
Publish Date 2013-11-13 08:37
Citation Oshiro Y, Takahashi K, Sasaki R, Kondo T, Sakashita S, Ohkohchi N. Adjuvant surgery for advanced extrahepatic cholangiocarcinoma. World J Gastroenterol 2013; 19(40): 6934-6938
URL http://www.wjgnet.com/1007-9327/full/v19/i40/6934.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i40.6934
Full Article (PDF) WJG-19-6934.pdf
Manuscript File 4354-Review.docx
Answering Reviewers 4354-Answering reviewers.pdf
Copyright License Agreement 4354-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 4354-Language certificate.pdf
Peer-review Report 4354-Peer review(s).pdf
Scientific Editor Work List 4354-Scientific editor work list.doc